#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Does The Use of Levothyroxine in Women with Thyroid Peroxidase Antibodies Affect The Risk of Miscarriage and Premature Birth?

Women with thyroid peroxidase antibodies have a higher risk of miscarriage and premature birth, even if they have normal thyroid function. The British study presented below aimed to clarify whether the use of levothyroxine affects the incidence of these complications.
Source: Thyroid Disorders 10. 2. 2020

News Options for Anticoagulant Therapy During Catheter Ablation for Atrial Fibrillation: Safety and Efficiency of Bridging with Dabigatran Compared to Interruption of NOACs

Catheter ablation is an established method for treating supraventricular and ventricular arrhythmias. Patients with atrial fibrillation should also use anticoagulant therapy to prevent thromboembolic events, even during ablation. The number of patients being treated with new anticoagulants (NOACs) is increasing, but the use of direct factor Xa inhibitors poses a risk of life-threatening bleeding during catheterization if a specific antidote is not available at the healthcare facility. Options to prevent this complication include short-term switching to dabigatran or complete interruption of NOACs therapy with temporary heparin support. The aim of the presented study was to compare the safety and feasibility of both methods.
Source: Anticoagulant Treatment 23. 6. 2020

News What Next for Patients with CLL After Stopping Venetoclax?

Standard care for untreated patients with chronic lymphocytic leukemia (CLL) is therapy based on venetoclax. However, managing further treatment when venetoclax needs to be discontinued remains a relatively unexplored area without standardized protocols.
Source: Chronic Lymphocytic Leukemia 17. 7. 2020

News Optimization of Romiplostim Administration in ITP Treatment

In their newly published review article, authors from several American institutions summarize findings on the role of romiplostim in the treatment of immune thrombocytopenia (ITP) and its efficacy and safety. Among other things, they provide the latest data on its early administration as early as 3 months after the onset of the disease, discuss the possibility of achieving remission without the need for further treatment, and also address practical aspects of therapy.
Source: Immune Thrombocytopenia 22. 10. 2021

Journal articles Assessment of health status for the purposes of benefi ts and social security services for people with lung cancer and the economic impact of this disease on social security in the Czech Republic

Author of the article: M. Bosák, M. Másilková, V. Kahoun Source: Klinická onkologie | 2/2021 16. 4. 2021

News Orally Administered Berotralstat in the Prevention of Hereditary Angioedema Attacks

Berotralstat is an oral medication administered once daily, developed to prevent hereditary angioedema (HAE) attacks. It is a kallikrein protease inhibitor, which plays a key role in the pathogenesis of this disease. A phase III clinical trial, with results recently published in the Journal of Allergy and Clinical Immunology, evaluated the efficacy and safety of two dosing regimens of berotralstat compared to placebo in patients with HAE.
Source: Hereditary Angioedema 25. 2. 2022

News Study AMPLIFY Confirmed Safety and Efficacy of Fixed Combination Aclidinium/Formoterol in COPD Therapy

The randomized double-blind phase III AMPLIFY study compared the efficacy of a fixed combination of formoterol/aclidinium with monotherapy of the individual components or with tiotropium in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
Source: Treatment of Asthma and COPD 15. 7. 2020

News HAE and its Management in Pediatric Patients

Hereditary angioedema (HAE) can be encountered in the emergency room as well as in specialist practices. Patients with this rare disease are often incorrectly diagnosed with other, more common conditions, and it can take many years before they receive the correct diagnosis. This is because the symptoms of HAE overlap with those of other illnesses. What should pediatricians, otolaryngologists, and gastroenterologists be aware of? To provide a better understanding of HAE symptoms from the perspective of various specialties and emphasize the importance of interdisciplinary collaboration for the correct diagnosis and care of patients with HAE, a professional webinar was held. We have prepared a summary of the most important points for you.
Source: Hereditary Angioedema 19. 11. 2021

News Retention – An Overlooked Parameter of Incontinence Products

In the Czech Republic and other European countries, the main criterion when choosing an incontinence product, apart from its size, is primarily absorption. This defines the amount of fluid the product can hold in its absorbent core, but it does not tell anything about its retention capability. What is retention and why is it important to know?
Source: Incontinence 9. 4. 2021

News Increase in Hematocrit During Empagliflozin Treatment in a Diabetic Patient with Severe Anemia − A Case Study

In a case study involving a 78-year-old diabetic patient, where only the administration of empagliflozin led to the correction of severe anemia of unknown origin, Polish authors demonstrate the previously described pleiotropic effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) on increasing hematocrit levels.
Source: Heart Failure 26. 7. 2022

News Heart Failure in Light of New ESC Guidelines

Dear Doctor, The Czech Society of Internal Medicine ČLS JEP invites you to watch the symposium, which will take place on Wednesday, November 3rd at 5 PM.
You can find more information in the attached invitation below.
Source: Anticoagulant Treatment 27. 10. 2021

News What Response to the COVID-19 Vaccine Can Be Expected in Patients After Stem Cell Transplantation?

During the recent virtual congress of the European Society for Blood and Marrow Transplantation (EBMT 2022), a study by Saudi experts was presented that explored the response to vaccination against SARS-CoV-2, the causative agent of COVID-19, in patients who had undergone stem cell transplantation (SCT).
Source: Hematologic Malignancies 27. 4. 2022

News Impact of Primary Tumor Location and Early Regression on Survival in Patients with Metastatic CRC

Results from recent clinical studies suggest the prognostic significance of the primary tumor location on the survival of patients with metastatic colorectal cancer (mCRC). A retrospective analysis of data from a single-arm open-label phase II clinical trial evaluated the impact of primary tumor location and its early regression (ETS - early tumor shrinkage) on the survival of patients with mCRC who received a combination of chemotherapy (FOLFIRI regimen) and targeted biological therapy (panitumumab).
Source: Colorectal Cancer 15. 9. 2020

News Prophylaxis of Thromboembolism with Low-Molecular-Weight Heparins in Oncology Patients: Efficacy and Safety of Doses Adjusted According to Anti-Xa Activity

Oncological patients undergoing surgical procedures are observed to have a high risk of thromboembolic complications. Recommended prophylactic dosing of low-molecular-weight heparins (LMWH) is often associated with subprophylactic anti-Xa activity in high-risk patients. A recently published study evaluated the efficacy and safety of administering enoxaparin in doses adjusted according to the measured anti-Xa activity.
Source: Thromboprophylaxis 28. 1. 2020

News Romiplostim in Routine Clinical Use among Patients with ITP in European Countries − Fresh Data Analysis

Data from randomized clinical trials have shown that romiplostim is an effective medication for many patients not only with acute or persistent immune thrombocytopenia (ITP) but also for much more complicated patients with chronic ITP. In April 2021, data on the efficacy and safety of romiplostim from European clinical practice were published.
Source: Immune Thrombocytopenia 30. 11. 2021

News Study PLATON: romiplostim in patients with ITP in real clinical practice

Recently, the results of the PLATON study with romiplostim, which was conducted in Central and Eastern European countries including the Czech Republic, were published. It was an observational non-interventional cohort study from real practice, and romiplostim was used within its approved indication.
Source: Immune Thrombocytopenia 8. 6. 2020

Journal articles Can contraception to impact demographics dates?

Author of the article: Tomáš Fait Source: Praktická gynekologie | 4/2013 13. 12. 2013

News Do Gliflozins Affect the Need to Use Diuretics?

Sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) have advanced from their initial role in reducing hyperglycemia in the treatment of type 2 diabetes mellitus (DM2) to antidiabetics with proven cardioprotective effects and additional indications for patients with heart failure or chronic kidney disease. Last year, the CHAMPION cohort study was published, which investigated the impact of empagliflozin use on diuretic prescribing and mid-term laboratory results in patients concurrently treated with diuretics.
Source: Heart Failure 1. 10. 2023

News N9-GP in Previously Treated Pediatric Patients with Hemophilia B – Extended Follow-up

An analysis of extended treatment with nonacog alfa pegol (N9-GP) in pediatric patients with hemophilia B evaluated the long-term safety and effectiveness of this prophylactic modality.
Source: Hemophilia with Movement 4. 10. 2023

News Position of the Aclidinium-Bromide/Formoterol-Fumarate Combination in COPD Treatment According to Current Recommendations

Dual bronchodilator therapy, which combines long-acting muscarinic antagonists (LAMA) and long-acting β-agonists (LABA), has become an integral part of the treatment for chronic obstructive pulmonary disease (COPD). Growing evidence of the efficacy and safety of the fixed combination of aclidinium-bromide/formoterol-fumarate demonstrates that this treatment meets patient needs and the current GOLD recommendations from 2019.
Source: Treatment of Asthma and COPD 3. 6. 2021

News Risk Factors for Renal Cancer Formation After Kidney Transplantation

German authors in the below-cited work identified modifiable risk factors associated with the development of renal cell carcinoma (RCC) de novo in patients after kidney transplantation.
Source: Kidney Carcinoma 5. 11. 2021

News Incidence of Glaucoma or Suspected Glaucoma Within the First Year Post-Lensectomy in Children and Treatment Approach to These Patients

The aim of the study conducted by a team of authors from several American universities was to determine the approximate incidence of glaucoma or suspected glaucoma in children under 13 years old within the first year after lensectomy and to describe the management of care for these patients.
Source: Glaucoma 12. 2. 2020

News Romiplostim in ITP Treatment – Data from German Clinical Practice

Real-world clinical practice data from Germany confirm the beneficial effect and safety profile of romiplostim in patients with immune thrombocytopenia (ITP), both newly diagnosed, persistent, and chronic.
Source: Immune Thrombocytopenia 2. 10. 2023

News Long-term Efficacy, Safety, and Tolerability of Normal Human IgG with Facilitated Absorption in Patients with Humoral Immunodeficiency

The treatment of patients with humoral immunodeficiency is long-term and therefore needs to be not only effective but also safe and well-tolerated. Below, we present the outcomes from an Italian real-world clinical practice study evaluating the efficacy, safety, and tolerability of human immunoglobulin for facilitated subcutaneous administration and patient satisfaction with this therapy.
Source: Primary and Secondary Immunodeficiencies 12. 1. 2023

News Change in Mutation Characteristics of NSCLC Detected by Liquid Biopsy – Case Study

Due to changes in mutations during the progression of metastatic non-small cell lung cancer (NSCLC) or to assess treatment response, liquid biopsy is essential for monitoring, as its results can affect the selection of targeted therapy. American authors present the case of a patient with advanced NSCLC initially treated with alectinib due to positive ALK gene rearrangement, whose therapy was switched to sotorasib after disease progression and the finding of the KRAS oncogene G12C mutation in a liquid biopsy.
Source: Lung Cancer 19. 6. 2023

1 9 10 11 12 13 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#